1 twenty-eight healthy male participants volunteered in this
randomized double-blind, placebo-controlled,
between-group st
2 D to Prevent Severe Asthma Exacerbations (VDKA) Study was a
randomized, double-blind, placebo-controlled clinical trial o
3 This study is a
randomized, double-blind, placebo-controlled clinical trial.
4 tric dysrhythmias to normal rhythms.(9) In a preregistered,
randomized, double-blind, placebo-controlled crossover design
5 fter 4 weeks' treatment with empagliflozin and placebo in a
randomized, double-blind, placebo-controlled crossover study.
6 an age = 32.6 years +/- 6.11; 1 female) completed a phase-1
randomized, double-blind, placebo-controlled,
crossover study
7 This study was a
randomized, double-blind, placebo-controlled,
crossover trial
8 ition in Combination With Diuretics in Heart Failure) was a
randomized, double-blind, placebo-controlled,
crossover trial
9 A
randomized, double-blinded, placebo-controlled,
crossover int
10 01 was tested in cytomegalovirus-naive, healthy adults in a
randomized, double-blind, placebo-controlled,
dose-escalation
11 We conducted a
randomized, double-blind, placebo-controlled,
dose-ranging tr
12 administering omalizumab versus placebo to asthmatics in a
randomized, double-blind placebo-controlled investigation.
13 In this investigator-initiated,
randomized, double-blind, placebo-controlled,
multicenter tri
14 DESIGN, SETTING, AND PARTICIPANTS: Phase 2b
randomized, double-blind, placebo-controlled,
multicenter tri
15 A single site,
randomized, double-blind, placebo-controlled,
parallel study
16 In a
randomized, double-blind, placebo-controlled,
parallel-group
17 The second was a
randomized, double-blind, placebo-controlled pharmacologic in
18 We conducted a
randomized, double-blind, placebo-controlled phase 3 trial in
19 DESIGN, SETTING, AND PARTICIPANTS: CAPACITY HFpEF was a
randomized, double-blind, placebo-controlled,
phase 2 trial.
20 sant therapy (ADT) in FORWARD-4 and FORWARD-5: two phase 3,
randomized, double-blind, placebo-controlled studies that uti
21 944 women with HIV participating in a
randomized, double-blind, placebo-controlled study comparing
22 d significantly reduced liver fat content in a multicenter,
randomized, double-blind, placebo-controlled study in patient
23 This single-center, phase 2,
randomized, double-blind, placebo-controlled study investigat
24 We describe a first-in-human,
randomized, double-blind, placebo-controlled study investigat
25 In a
randomized double-blind, placebo-controlled,
time course SLIT
26 A phase 1-2
randomized double-blind placebo-controlled trial enrolled 252
27 The authors conducted an 8-week
randomized double-blind placebo-controlled trial of adjunctiv
28 We performed the first
randomized double-blind placebo-controlled trial to evaluate
29 nt with ciprofloxacin, at Day 14.Methods: In a multicenter,
randomized double-blind placebo-controlled trial, we studied
30 We conducted a
randomized double-blinded placebo-controlled trial to determi
31 We designed a multicenter,
randomized, double-blind, placebo-controlled trial (the SUGAR
32 We conducted a
randomized, double-blind, placebo-controlled trial across the
33 ODYSSEY OUTCOMES was a
randomized, double-blind, placebo-controlled trial comparing
34 This was a
randomized, double-blind, placebo-controlled trial in which p
35 This
randomized, double-blind, placebo-controlled trial included p
36 FOURIER was a
randomized, double-blind, placebo-controlled trial involving
37 This was a multicenter,
randomized, double-blind, placebo-controlled trial involving
38 We performed a
randomized, double-blind, placebo-controlled trial involving
39 To test this, we conducted a
randomized, double-blind, placebo-controlled trial of pioglit
40 We performed a 12-month,
randomized, double-blind, placebo-controlled trial of pomegra
41 We conducted a
randomized, double-blind, placebo-controlled trial to assess
42 We conducted a 24-week,
randomized, double-blind, placebo-controlled trial to evaluat
43 A factorial,
randomized, double-blind, placebo-controlled trial was conduc
44 We hence conducted a
randomized, double-blind, placebo-controlled trial with newly
45 DESIGN, SETTING, AND PARTICIPANTS: A
randomized, double-blind, placebo-controlled trial, conducted
46 In this phase 3,
randomized, double-blind, placebo-controlled trial, we assign
47 In a phase 2,
randomized, double-blind, placebo-controlled trial, we random
48 We performed a
randomized, double-blinded, placebo-controlled trial of 5110
49 A
randomized, double-blind, placebo-controlled,
two-way crossov
50 data from the Vitamin D Antenatal Asthma Reduction Trial, a
randomized, double-blinded, placebo-controlled VD supplementa